Seelos Therapeutics Receives FDA Fast Track Designation for Intranasal Racemic Ketamine (SLS-002)
18 nov. 2019 08h00 HE
|
Seelos Therapeutics, Inc.
NEW YORK, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...
American BriVision Announces Issuance of a Full Clinical Study Report (CSR) for ABV-1504 for Major Depressive Disorder Phase II Study
14 nov. 2019 13h22 HE
|
American BriVision Holding Corporation
PDC-1421 high-dose data meets primary endpoint on MADRS scale in ITT clinical trial population PDC-1421 low-dose and PDC-1421 high-dose each proved safe, were well-tolerated, and had no...
TMS Program Hosts Open House to Introduce Deep Transcranial Magnetic Stimulation (Deep TMS) Helmet to Treat Major Depressive Disorder (MDD) and Obsessive-Compulsive Disorder (OCD)
12 nov. 2019 09h00 HE
|
TMS Program
CHERRY HILL, N.J., Nov. 12, 2019 (GLOBE NEWSWIRE) -- TMS Program, a mental health clinic that provides treatments to a wide range of psychiatric disorders, today announced that it will host an open...
Seelos Therapeutics Reports Q3 2019 Pipeline Update
08 nov. 2019 07h00 HE
|
Seelos Therapeutics, Inc.
NEW YORK, Nov. 08, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company, today released its third quarter pipeline update. “Seelos continued...
Axsome Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Update
07 nov. 2019 07h00 HE
|
Axsome Therapeutics, Inc.
GEMINI Phase 3 placebo-controlled trial of AXS-05 in MDD completed enrollment and on track for readout of topline results by year-end 2019 STRIDE-1 Phase 3 trial of AXS-05 in TRD to conclude patient...
Seelos Therapeutics to Participate in Upcoming Investor Conferences in December
01 nov. 2019 10h00 HE
|
Seelos Therapeutics, Inc.
NEW YORK, Nov. 01, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company, announced today that it will participate in the Evercore ISI 2nd...
TMS NW Hosts Open House Event to Commemorate Two Year Anniversary
30 oct. 2019 12h00 HE
|
TMS NW
VANCOUVER, Wash., Oct. 30, 2019 (GLOBE NEWSWIRE) -- TMS NW, a full-service mental health clinic with advanced treatments for mental health disorders, announced today that it will host an open house...
A Stepping Stone Hosts Open House to Introduce Newly Offered FDA-Cleared Helmet to Treat Major Depressive Disorder (MDD)
29 oct. 2019 11h00 HE
|
BrainsWay Ltd.
GREENWOOD VILLAGE, Colo., Oct. 29, 2019 (GLOBE NEWSWIRE) -- A Stepping Stone, a full-service outpatient mental health clinic with advanced treatments for mental health disorders, announced today...
Seelos Therapeutics Announces Amendment of SLS-002 Agreement
21 oct. 2019 09h00 HE
|
Seelos Therapeutics, Inc.
Seelos Plans to Study SLS-002 Initially in Suicidality in Major Depressive Disorder NEW YORK, Oct. 21, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage...
Seelos Therapeutics to Participate in Upcoming Investor Conference in November
18 oct. 2019 09h00 HE
|
Seelos Therapeutics, Inc.
NEW YORK, Oct. 18, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company, announced today that it will participate in the Jefferies 2019...